Strengthening Families & Communities LLC Acquires 114 Shares of Danaher Corporation (NYSE:DHR)

Strengthening Families & Communities LLC increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 81.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 254 shares of the conglomerate’s stock after purchasing an additional 114 shares during the period. Strengthening Families & Communities LLC’s holdings in Danaher were worth $52,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of DHR. GHP Investment Advisors Inc. raised its stake in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 99 shares during the period. Heck Capital Advisors LLC acquired a new position in Danaher in the 4th quarter valued at $27,000. Sierra Ocean LLC grew its holdings in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after buying an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher during the 1st quarter worth $31,000. Finally, Dunhill Financial LLC grew its holdings in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 67 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.1%

DHR stock opened at $200.70 on Monday. The stock’s fifty day simple moving average is $198.46 and its two-hundred day simple moving average is $200.62. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The stock has a market cap of $143.71 billion, a P/E ratio of 42.70, a P/E/G ratio of 2.80 and a beta of 0.73.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same quarter in the previous year, the firm earned $1.72 earnings per share. The business’s revenue was up 3.4% on a year-over-year basis. Analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on DHR shares. Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective on the stock in a research note on Friday, July 11th. The Goldman Sachs Group cut their price target on Danaher from $260.00 to $240.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. cut their price target on Danaher from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 22nd. Jefferies Financial Group cut their price objective on Danaher from $260.00 to $230.00 and set a “buy” rating on the stock in a research note on Tuesday, April 22nd. Finally, Argus cut their price objective on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.